Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 9.27 and a target value of HKD 15.00 [3][21]. Core Insights - The company achieved its first annual profit in 2025, with revenue of RMB 803 million, a year-on-year increase of 201.2%, and a net profit of RMB 135 million, compared to a loss of RMB 1.515 billion in the previous year [7][8]. - The rapid revenue growth is driven by the drug discovery solutions segment, which generated RMB 538 million in revenue, up 418.9% year-on-year, and the AI4S smart solutions segment, which earned RMB 265 million, a 62.6% increase [7][8]. - The company is enhancing its AI4S capabilities and accelerating its global expansion, aiming to establish a platform company that can replicate its model across various industries, including pharmaceuticals, new materials, and consumer health [10][19]. Financial Projections - Revenue projections for 2026 to 2028 are RMB 1.137 billion, RMB 1.535 billion, and RMB 2.026 billion, respectively, representing year-on-year growth rates of 42%, 35%, and 32% [16][21]. - The drug discovery solutions segment is expected to continue driving growth, with projected revenues of RMB 753 million, RMB 1.017 billion, and RMB 1.352 billion for the same period [15][21]. - The AI4S smart solutions segment is also anticipated to grow, with expected revenues of RMB 384 million, RMB 518 million, and RMB 674 million from 2026 to 2028 [15][21]. Business Model and Strategy - The company is transitioning from a single project service model to a platform licensing model, which includes milestone payments and revenue sharing, enhancing its long-term commercial value [9][10]. - The company has established high-value collaborations with international pharmaceutical companies, indicating a shift towards a more integrated and scalable business model [9][10]. - The report highlights the company's strong cash reserves, which will support its overseas expansion and technology acquisitions, further solidifying its market position [10][19].

Core Viewpoint - Jingtai Technology has officially entered the stage of scalable value realization, marking a significant milestone in its growth trajectory as it becomes the first profitable AI application company listed in Hong Kong [5][7]. Financial Performance - In 2025, Jingtai Technology achieved a revenue of 803 million RMB, representing a year-on-year growth of 201.2%. The net profit reached 135 million RMB, with an adjusted net profit of 258 million RMB, indicating its first annual profitability [5]. - As of December 31, 2025, the company had a cash balance of 7.069 billion RMB and a net issuance of convertible bonds amounting to 2.562 billion RMB, providing a solid financial foundation for ongoing R&D investments [6]. Business Development - The number of revenue-generating clients increased by 62% year-on-year, covering 17 of the top 20 global pharmaceutical companies, with cumulative cooperation amounts reaching hundreds of billions of RMB [6]. - Jingtai Technology has empowered and incubated over five first-in-class/best-in-class innovative pipelines, entering clinical and IND-enabling stages across various disease areas, including oncology and chronic diseases [6]. Strategic Upgrades - The AI4S smart solution business saw a revenue increase of 62.6% to 265 million RMB in 2025, reflecting a strategic upgrade from traditional delivery to a comprehensive intelligent R&D system [12]. - The company has transitioned its business model from single project services to a strategy of "platform licensing + joint development + milestone revenue," laying a solid foundation for sustainable growth [13]. Technological Integration - Jingtai Technology's "AI + Robotics + Multi-Agent" system has created a self-evolving R&D model, enhancing efficiency in drug discovery and development [15][19]. - The company has developed over 200 industry-specific AI models, covering the entire chain from target discovery to preclinical candidate screening, supported by a robust data asset system [20]. Cross-Industry Expansion - Jingtai Technology is accelerating the application of its core capabilities into consumer health and new materials sectors, demonstrating the platform's universal value [22]. - In the consumer health sector, the company has registered innovative external molecules for hair growth, achieving significant market recognition [22]. - In the photovoltaic sector, a strategic partnership with Jinko Solar aims to develop AI-driven high-throughput solar cell manufacturing lines, showcasing the company's commitment to next-generation technology [24][25]. Future Outlook - The company plans to deepen the flywheel effect of technological iteration, leveraging its AI models and automated laboratories to maintain its leading position in the AI for Science field while expanding into broader sectors [27].